Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$6.93 USD

6.93
3,925,694

-0.06 (-0.86%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $6.94 +0.01 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?

by Zacks Equity Research

Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data

by Zacks Equity Research

Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.

Zacks Equity Research

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

by Zacks Equity Research

ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.

Zacks Equity Research

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

by Zacks Equity Research

MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Amicus (FOLD) Banks on Galafold, High Dependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales. However, overdependence on Galafold for revenues remains a concern.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

by Zacks Equity Research

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Zacks Equity Research

Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 100% and 4.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Certara (CERT) delivered earnings and revenue surprises of -36.36% and 1.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.

Zacks Equity Research

Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.

Zacks Equity Research

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

by Zacks Equity Research

Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.

Zacks Equity Research

Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clene (CLNN) delivered earnings and revenue surprises of 0% and 54.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

by Zacks Equity Research

Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -83.33% and 0.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Amicus' (FOLD) lead drug, Galafold, are rising consistently. Also, the recent approval of the Pompe disease drug combination, Pombiliti + Opfolda, is a positive.

Zacks Equity Research

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

by Zacks Equity Research

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.